Royal Bank of Canada Forecasts Strong Price Appreciation for Pyxis Oncology (NASDAQ:PYXS) Stock

Pyxis Oncology (NASDAQ:PYXS) had its price objective boosted by Royal Bank of Canada from $7.00 to $10.00 in a research note published on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other analysts also recently weighed in on the company. Stephens initiated coverage on Pyxis Oncology in a report on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price for the company. Stifel Nicolaus started coverage on Pyxis Oncology in a research note on Thursday, August 8th. They set a “buy” rating and a $10.00 target price for the company. William Blair downgraded Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Thursday. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Pyxis Oncology Trading Down 3.8 %

Shares of Pyxis Oncology stock traded down $0.08 on Thursday, hitting $2.02. The stock had a trading volume of 403,797 shares, compared to its average volume of 717,285. Pyxis Oncology has a 52-week low of $1.35 and a 52-week high of $6.85. The stock has a market cap of $120.13 million, a price-to-earnings ratio of -2.07 and a beta of 1.27. The company’s 50 day moving average price is $3.68 and its 200 day moving average price is $3.63.

Institutional Investors Weigh In On Pyxis Oncology

A number of large investors have recently bought and sold shares of PYXS. MetLife Investment Management LLC boosted its holdings in shares of Pyxis Oncology by 41.1% during the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares during the last quarter. Pier 88 Investment Partners LLC boosted its holdings in shares of Pyxis Oncology by 7.0% during the third quarter. Pier 88 Investment Partners LLC now owns 121,610 shares of the company’s stock worth $446,000 after purchasing an additional 7,910 shares during the last quarter. Fullcircle Wealth LLC acquired a new stake in shares of Pyxis Oncology during the second quarter worth $40,000. SG Americas Securities LLC acquired a new stake in shares of Pyxis Oncology during the first quarter worth $59,000. Finally, Jane Street Group LLC boosted its holdings in shares of Pyxis Oncology by 40.8% during the third quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock worth $182,000 after purchasing an additional 14,349 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.